**Supplemental Digital Content 2 - Table 2. Inclusion and exclusion criteria**

|  |
| --- |
| ***Inclusion criteria:*** |
| 1. Degenerative disease of one or two lumbar discs with predominant back pain after conservative treatment (physical and medical) for over 6 months. |
| 2. Fibrous ring capable of holding the cell implantation, demonstrated by discography (stages 2, 3 and 4 of Adams) (30). |
| 3. Decrease of disc height of more than 50% (radiographic measurement in side image). |
| 4. Absence of spinal infection. |
| 5. Haematological and biochemical analysis wit no significant alterations that contraindicates intervention. |
| 6. The patient is able to understand the nature of the study. |
| 7. Informed written consent of the patient. |
|  |
| ***Exclusion criteria:*** |
| 1. Age over 65 or under 18 or legally dependent |
| 2. Infection signs or positive serology for HIV, hepatitis and syphilis. |
| 3. Allergy to gentamicin, or to bovine, cattle or horse serum. |
| 4. Congenital or acquired diseases leading to spine deformations that may upset cell application. |
| 5. Spinal segmental instability, spinal canal stenos, isthmus pathology and other conditions that may compromise the study |
| 6. Modic changes on MRI images (31). |
| 7. Overweight with body mass index (mass in Kg/size in m2) greater than 30.5 (obesity grade II). |
| 8. Pregnancy or breast-feeding |
| 9. Neoplasia |
| 10. Immunosuppression |
| 11. Participation in another clinical trial or treatment with another investigational product within 30 days prior to inclusion in the study. |
| 12. Other conditions that may, according to medical criteria, discourage participation in the study. |